Comparison of the New Antihistamine Acrivastine (BW 825C) versus Cyproheptadine in the Treatment of Idiopathic Cold Urticaria
作者:
Heikki Neittaanmäki,
Jorma E. Fräki,
John R. Gibson,
期刊:
Dermatology
(Karger Available online 1988)
卷期:
Volume 177,
issue 2
页码: 98-103
ISSN:1018-8665
年代: 1988
DOI:10.1159/000248523
出版商: S. Karger AG
关键词: Cold urticaria;Acrivastine;Histamine H1-receptor blockers
数据来源: Karger
摘要:
A double-blind, crossover trial with a new triprolidine derivative, acrivastine (BW 825C; 8 mg 3 times daily), cyproheptadine (4 mg 3 times daily) and placebo was carried out in 18 patients suffering from idiopathic cold urticaria. Acrivastine and cyproheptadine significantly (p < 0.01) reduced weal areas following ice cube challenge when compared to placebo. Acrivastine was found to be significantly more effective (p < 0.01) than cyproheptadine in reducing weal areas. Furthermore, cyproheptadine caused significantly more drowsiness than acrivastine (p = 0.021) or placebo (p = 0.013), which did not differ from each other. This study shows that acrivastine is an effective agent in the treatment of cold urticaria and suggests that acrivastine in the dose used lacks adverse effects, such as drowsiness, traditionally associated with antihistamine therapy.
点击下载:
PDF
(1794KB)
返 回